The global market for Live Brucellosis Vaccines is witnessing steady growth driven by increasing awareness about animal health and the growing demand for controlling brucellosis, a zoonotic disease that affects livestock and can be transmitted to humans. Brucellosis remains a significant concern in the agricultural sector, especially in countries with large livestock populations. As a result, vaccination programs for cattle, sheep, and pigs are critical in controlling the spread of this disease. Various vaccine strains, including RB-51, S19, S2, A19, and Rev. I, are in demand due to their effectiveness in preventing brucellosis in different animal species.
Market Size
The Live Brucellosis Vaccine market is expected to grow at a compound annual growth rate (CAGR) of 4.5% to 6.5% over the forecast period of 2025-2030. This growth is primarily driven by ongoing vaccination campaigns, particularly in developing regions, as well as increasing government support for livestock health initiatives.
Market Share & Trends Analysis
By Product Type
The Live Brucellosis Vaccine market is segmented by vaccine strain, with several key strains dominating the market:
- Strain RB-51: This strain is the most widely used in the market due to its effectiveness and lower likelihood of causing adverse reactions in vaccinated animals. The RB-51 strain is expected to hold a market share of 30% to 35%,with a CAGR of 5.0% to 6.0%.
- Strain S19: Historically one of the most used strains, S19 is still in demand due to its established track record in cattle. It holds a market share of 25% to 30% and is projected to grow at a CAGR of 4.5% to 5.5% over the forecast period.
- Strain S2: This strain is used primarily for sheep and is expected to maintain a market share of 10% to 15%,with a growth rate of 4.0% to 5.0%.
- Strain A19: Primarily used for pigs, this strain is forecast to have a market share of 10% to 15%,growing at a CAGR of 4.5% to 5.5%.
- Strain Rev. I: A newer vaccine strain used in specific regions, Rev. I is expected to capture 5% to 10% of the market, with a CAGR of 5.5% to 6.5%.
By Application
The applications for Live Brucellosis Vaccines include cattle, sheep, pigs, and other livestock species:
- Cattle: The largest segment, cattle vaccination remains a critical part of brucellosis control programs. This segment is expected to account for 50% to 55% of the market share, with a CAGR of 5.0% to 6.0%.
- Sheep: The sheep vaccination segment is growing as brucellosis continues to impact sheep farming in certain regions. It is projected to hold 20% to 25% of the market share, growing at a CAGR of 4.5% to 5.5%.
- Pig: Brucellosis vaccination in pigs is crucial for disease prevention in swine farms, contributing around 15% to 20% of the market. This segment is expected to grow at a CAGR of 4.0% to 5.0%.
- Others: Other applications, including in goats and other livestock species, make up a smaller segment of the market, accounting for 5% to 10% of the market share, with a CAGR of 3.5% to 4.5%.
By Key Players
The Live Brucellosis Vaccine market is competitive, with several leading players driving innovation and supply:
- CZ Vaccines: A prominent manufacturer of veterinary vaccines, including those for brucellosis, contributing significantly to the global market.
- MSD Animal Health: A major player in the animal health industry, MSD offers a range of brucellosis vaccines for livestock.
- Ceva: Known for its veterinary vaccine solutions, Ceva is a key player in the development of brucellosis vaccines.
- Colorado Serum: A leading supplier of animal health products, including vaccines for brucellosis prevention.
- Tecnovax: Specializes in providing high-quality vaccines for livestock, with a focus on brucellosis control.
- Syva: A key manufacturer of veterinary vaccines, including for brucellosis, catering to the global market.
- Shchelkovo Biocombinat: A major producer of veterinary vaccines, including live brucellosis vaccines, in Russia and surrounding regions.
- Jinyu Baoling: A Chinese producer of vaccines, contributing to the Asian market for animal health products.
- Biovet: Known for its strong presence in the Latin American and European markets, Biovet offers brucellosis vaccines to various regions.
- CAVAC: A leader in the development and production of animal vaccines, including brucellosis vaccines.
- VETAL: Specializes in animal health products, including vaccines for brucellosis prevention.
- Indian Immunologicals: A major player in India, producing vaccines for a range of animal diseases, including brucellosis.
- Dollvet: Known for producing veterinary vaccines, including for brucellosis, in emerging markets.
- Hester Biosciences: Focused on producing vaccines for various animal diseases, including brucellosis, with a strong market presence in India.
- Qilu Animal Health: A Chinese company producing veterinary vaccines, including those for brucellosis, for domestic and international markets.
- Auleon Biologicals: Known for producing brucellosis vaccines and other biologics for animal health.
By Region
The Live Brucellosis Vaccine market is influenced by regional vaccination programs and disease control efforts:
- North America: Dominates the market, accounting for 30% to 35% of the market share. This region is expected to grow at a CAGR of 4.5% to 5.5%,driven by ongoing disease prevention and livestock health initiatives.
- Europe: A key market for brucellosis vaccines, with significant demand in both Eastern and Western Europe. Europe is expected to hold 20% to 25% of the market share, growing at a CAGR of 4.0% to 5.0%.
- Asia-Pacific: Rapidly growing market, particularly in China and India, where large livestock populations drive demand. The region is forecast to grow at a CAGR of 5.0% to 6.0%,with a market share of 25% to 30%.
- Latin America: A major market for brucellosis vaccination programs, particularly in Brazil and Argentina. Latin America holds 15% to 20% of the market share, with a projected growth rate of 4.5% to 5.5%.
- Middle East & Africa: An emerging market for brucellosis vaccines, expected to hold 5% to 10% of the market share, growing at a CAGR of 4.0% to 5.0%.
Segment Forecasts (2025-2030)
Growth in Key Segments
- Strain RB-51: Expected to continue its dominance with a CAGR of 5.0% to 6.0%.
- Cattle Application: Projected to remain the largest segment, growing at a CAGR of 5.0% to 6.0%.
- Asia-Pacific Region: Expected to experience the highest growth rate in the market, with a CAGR of 5.0% to 6.0%.
This product will be delivered within 1-3 business days.
Table of Contents
Companies Mentioned
- CZ Vaccines
- MSD
- Ceva
- Colorado Serum
- Tecnovax
- Syva
- Shchelkovo Biocombinat
- Jinyu Baoling
- Biovet
- CAVAC
- VETAL
- Indian Immunologicals
- Dollvet
- Hester Biosciences
- Qilu Animal Health
- Auleon Biologicals
